Anika Therapeutics (ANIK) Total Non-Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has reported Total Non-Current Liabilities for 17 consecutive years, with $45.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 15.81% year-over-year to $45.5 million in Q2 2026; TTM through Jun 2026 was $45.5 million, a 15.81% increase from a year earlier, with the FY2025 full-year figure at $46.1 million, down 3.91% from the prior year.
• Total Non-Current Liabilities was $45.5 million for Q2 2026 at Anika Therapeutics, up from $44.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $67.4 million in Q2 2022 and troughed at $39.3 million in Q2 2025.
• A 5-year average of $52.4 million and a median of $53.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slumped 30.15% in 2022 and rose 15.81% in 2026, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $63.2 million in 2022, then retreated by 8.24% to $58.0 million in 2023, then declined by 17.22% to $48.0 million in 2024, then declined by 3.91% to $46.1 million in 2025, then retreated by 1.39% to $45.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $45.5 million (Q2 2026), $44.8 million (Q1 2026), and $46.1 million (Q4 2025), per Business Quant data.